188 related articles for article (PubMed ID: 20516559)
1. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Niu C; Bao H; Tolstykh T; Micolochick Steuer HM; Murakami E; Korba B; Furman PA
Antivir Ther; 2010; 15(3):401-12. PubMed ID: 20516559
[TBL] [Abstract][Full Text] [Related]
2. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Zhu Y; Curtis M; Qi X; Miller MD; Borroto-Esoda K
Antivir Chem Chemother; 2009; 19(4):165-76. PubMed ID: 19374144
[TBL] [Abstract][Full Text] [Related]
3. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.
Seifer M; Patty A; Serra I; Li B; Standring DN
Antiviral Res; 2009 Feb; 81(2):147-55. PubMed ID: 19028525
[TBL] [Abstract][Full Text] [Related]
4. New drugs for chronic hepatitis B: a review.
Palumbo E
Am J Ther; 2008; 15(2):167-72. PubMed ID: 18356637
[TBL] [Abstract][Full Text] [Related]
5. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.
Delaney WE; Yang H; Miller MD; Gibbs CS; Xiong S
Antimicrob Agents Chemother; 2004 Oct; 48(10):3702-10. PubMed ID: 15388423
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous detection of hepatitis B virus genotypes and mutations associated with resistance to lamivudine, adefovir, and telbivudine by the polymerase chain reaction-ligase detection reaction.
Wang YZ; Xiao JH; Liu LG; Ye CY; Shen HY; Xu TM; Zhu KZ
Braz J Infect Dis; 2011; 15(6):560-6. PubMed ID: 22218515
[TBL] [Abstract][Full Text] [Related]
7. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis B in patients with HIV infection].
Barreiro P; Martín-Carbonero L; García-Samaniego J
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():71-9. PubMed ID: 19100234
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.
Kwon SY; Park YK; Ahn SH; Cho ES; Choe WH; Lee CH; Kim BK; Ko SY; Choi HS; Park ES; Shin GC; Kim KH
J Virol; 2010 May; 84(9):4494-503. PubMed ID: 20164224
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
11. [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Buti M
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():32-8. PubMed ID: 19100229
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.
Menéndez-Arias L; Álvarez M; Pacheco B
Curr Opin Virol; 2014 Oct; 8():1-9. PubMed ID: 24814823
[TBL] [Abstract][Full Text] [Related]
13. [Management of antiviral-resistant chronic hepatitis B virus infection].
Yim HJ
Korean J Gastroenterol; 2008 Jun; 51(6):346-59. PubMed ID: 18604136
[TBL] [Abstract][Full Text] [Related]
14. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
Karatayli E; Karayalçin S; Karaaslan H; Kayhan H; Türkyilmaz AR; Sahin F; Yurdaydin C; Bozdayi AM
Antivir Ther; 2007; 12(5):761-8. PubMed ID: 17713159
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.
Yang H; Qi X; Sabogal A; Miller M; Xiong S; Delaney WE
Antivir Ther; 2005; 10(5):625-33. PubMed ID: 16152756
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
17. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.
Jones SA; Murakami E; Delaney W; Furman P; Hu J
Antimicrob Agents Chemother; 2013 Sep; 57(9):4181-9. PubMed ID: 23774432
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Lin Q; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):722-5. PubMed ID: 19874684
[No Abstract] [Full Text] [Related]
19. Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.
Schinazi RF; Bassit L; Clayton MM; Sun B; Kohler JJ; Obikhod A; Arzumanyan A; Feitelson MA
Antimicrob Agents Chemother; 2012 Dec; 56(12):6186-91. PubMed ID: 22985879
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Qi X; Xiong S; Yang H; Miller M; Delaney WE
Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
